Podcasts about active surveillance

April 11, 2025 Scott and Mark discuss questions that came into the PRS Helpdesk:Hello, Some years ago we were using the SRS urocuff. Can you tell me what the current codes are? I know this has been mentioned at the seminars- cannot find the slide :( ThanksHow are groups coding for the new Revi procedure for urge incontinence, urgency of urination, for both professional and facility fees. Is it best to use a 0817T or a 64581 w/ crosswalk? Cannot find a lot of information about this. Any feedback or suggestions would be greatly appreciated!I would like your thoughts about the use of Pelvic Floor rehab CPT code 91122 in a urology practice.  The company UroVal Inc. is promoting this  procedure for urologists to perform in the office setting.E/M question pls. Thank you!  For a follow up office visit, Pt has prostate cancer, and he is on "Active Surveillance".  For Problem Component of E/M, would you consider pCA on Active Surveillance is a Moderate VS a Low-level problem? (as opposed to personal history of pCA - Watchful Waiting).  I think it's a moderate level 4, but would like to hear your opinion, thank you!!Free Kidney Stone Coding CalculatorDownload NowPRS Billing and Other Services - Book a Call with Mark Painter or Marianne DescioseClick Here to Get More Information and Request a Quote Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.https://www.prsnetwork.com/joinuptp Click Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance. A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a radiation oncologist from the Sunnybrook Health Sciences Centre in Toronto, Canada, shared the details.

過年大魚大肉，棒免出來好難受？ 交給 FutureSalad 全清高纖新沙拉飲✨ 純天然蔬果製成 無藥性成分好安心 一包含有5.7g膳食纖維能促進腸道蠕動 6到12小時順暢排空！輕輕鬆鬆 一次全清

Recent research is changing how we manage low risk prostate cancer. In this BackTable Urology Podcast episode, Dr. Dan Lin, a urologist at the University of Washington, walks through contemporary diagnosis, surveillance, and management of Grade Group 2 prostate cancer with host Dr. Aditya Bagrodia. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS The doctors delve into real-world implementation of active surveillance, alongside the use of advanced diagnostics, biopsy methods, and personalized care plans. The conversation highlights the Canary Prostate Active Surveillance Study (PASS) and the prognostic role of biomarkers and genomic testing. Dr. Lin and Dr. Bagrodia also discuss how lifestyle factors such as diet impact cancer progression and how patients can be empowered to manage their disease. Strategies for transitioning patients off surveillance are highlighted. Finally, the two experts discuss insights from recent clinical trials like PIVOT, PROTECT, and SPCG and how they're impacting prostate cancer management. --- TIMESTAMPS 00:00 - Introduction 02:54 - Active Surveillance and Canary PASS Data 12:02 - Biopsy Considerations 19:44 - Active Surveillance Protocols 26:58 - Patient Concerns and Risk Reduction 30:52 - Transitioning Off Surveillance 33:39 - Grade Group 2: Treatment vs. Monitoring 46:24 - Surgical Considerations and Node Dissection 49:25 - Future Directions --- RESOURCES Veracyte https://www.veracyte.com/

This week, Faith is joined by urologist Dr. Alfred Winkler from NewYork-Presbyterian and Weill Cornell Medicine. They discuss prostate health and why it's so important for men to get screened for prostate cancer. Dr. Winkler also shares how it's among the most treatable cancers, and why some men can be under “active surveillance” and live with the slow-growing cancer with minimal impact on their lives.

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the June 25, 2024, issue.

This week, Faith is joined by urologist Dr. Alfred Winkler from NewYork-Presbyterian and Weill Cornell Medicine. They discuss prostate health and why it's so important for men to get screened for prostate cancer. Dr. Winkler also shares how it's among the most treatable cancers, and why some men can be under “active surveillance” and live with the slow-growing cancer with minimal impact on their lives.

As part of the 2024 Prostate Cancer Patient Conference, Dr. Kevin Shee discusses active surveillance in the management of localized prostate cancer, including typical schedule of surveillance monitoring, outcomes, and observations from its use at UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39757]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Kevin Shee discusses active surveillance in the management of localized prostate cancer, including typical schedule of surveillance monitoring, outcomes, and observations from its use at UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39757]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Kevin Shee discusses active surveillance in the management of localized prostate cancer, including typical schedule of surveillance monitoring, outcomes, and observations from its use at UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39757]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Kevin Shee discusses active surveillance in the management of localized prostate cancer, including typical schedule of surveillance monitoring, outcomes, and observations from its use at UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39757]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Kevin Shee discusses active surveillance in the management of localized prostate cancer, including typical schedule of surveillance monitoring, outcomes, and observations from its use at UCSF. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39757]

Join us as Sandhya Pruthi, MD talks us through basics of breast cancer, specifically how to share a new diagnosis with a patient, the spectrum of disease from favorable to more aggressive, and the basics of what to expect with initial treatment. Feel more confident sharing a new diagnosis of breast cancer and supporting your patients through this journey. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction 02:18 Getting to Know Dr Sandhya Pruthi 09:49 Picks of the Week 12:35 Case 1: Diagnosis and Treatment of ductal carcinoma in situ (DCIS) 21:24 Risk Stratification and Active Surveillance for DCIS 23:43 Genetic Testing Recommendations 28:08 Case 2: Evaluation and Diagnosis of a Breast Lump 39:14 Invasive Ductal Carcinoma 47:49 Initial Management of invasive ductal carcinoma (IDC) 48:19 Preoperative Discussion and MRI 49:19 Lumpectomy and Sentinel Lymph Node Biopsy 50:16 Radiation and Hormonal Adjuvant Therapy 51:46 Considerations for Chemotherapy 55:51 Signs of Late Recurrence or Metastasis 58:20 Screening Guidelines and Age 01:02:25 Importance of Breast Self-Awareness Credits Written and produced, Show Notes:  Molly Heublein MD Infographic and Cover Art: Edison Jyang Hosts: Molly Heublein MD, Era Kryzhanovskaya MD  Reviewer: Leah Witt, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Sandhya Pruthi MD Sponsor: Freed You can try Freed for free right now by going to freed.ai Listeners of Curbsiders can use code CURB50 for $50 off their first month.  Sponsor: Babbel Get 50% off at Babbel.com/CURB Sponsor: NetSuite Get your own KPI Checklist at NetSuite.com/CURBSIDERS

Before he created The Active Surveillor.com, Howard Wolinsky was a medical writer for the Chicago Sun-Times for nearly thirty years and a regular contributor to MedPage Today and Medscape. When he was diagnosed with Gleason 6 (now also called GG1) prostate he said no thanks as he was being rushed to take on a radical treatment option. Thirteen years down the road from his cancer diagnosis he is one of the country's most passionate advocates for active surveillance as a first (and possibly forever) step to indolent/favorable diagnoses of prostate cancer. Program Notes Links for Howard Wolinsky Howard Wolinsky on LinkedIn: linkedin.com/in/howardwolinsky Subscribe to The Active Surveillor: https://howardwolinsky.substack.com/ Howard's story in STAT News: https://www.statnews.com/2022/01/11/active-surveillance-for-prostate-cancer-the-gift-that-keeps-on-giving/ How Wolinsky became an advocate: https://www.medpagetoday.com/hematologyoncology/prostatecancer/63251 Links for Active Surveillance Feature on Active Surveillance in the New York Times: https://www.nytimes.com/2020/03/02/well/live/before-prostate-surgery-consider-active-surveillance.html Most men with low-risk prostate cancer now opt for acttive surveillance. or monitoring: https://www.medscape.com/viewarticle/974009 More than 60% of U.S. men with low-risk prostate cancer are now opting for active surveillance or monitoring: https://www.medscape.com/viewarticle/974009 Additional Links for Prostate Cancer Understanding why Secretary Austin wanted to keep his cancer a secret, but how he can help other patients by opening up: https://www.medpagetoday.com/special-reports/apatientsjourney/108309 The risks of transrectal biopsies: https://www.medpagetoday.com/special-reports/apatientsjourney/92201 The debate between transrectal and transperineal prostate biopsy methods: https://www.medscape.com/viewarticle/991496 Is low-risk disease really prostate cancer? https://www.medpagetoday.com/special-reports/apatientsjourney/90601

CME credits: 0.75 Valid until: 18-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/should-we-make-active-surveillance-more-active-for-localized-prostate-cancer/15914/ Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.

In this episode, Dr. Geo interviews Dr. Muhammad Minhaj Siddiqui, a renowned urologic oncology and robotic surgery specialist at the University of Maryland Medical Center. They explore the topic of active surveillance for prostate cancer, particularly focusing on Gleason 7 cases. Dr. Siddiqui shares his insights on determining the ideal candidates for active surveillance and discusses the correlation between prostate cancer metabolism and diet. They also discuss Dr. Siddiqui's research on the association between vasectomies and lethal prostate cancer. Join us for this enlightening conversation on urologic oncology and gain valuable insights from Dr. Siddiqui's expertise._______________Thank you to our sponsors.This episode is brought to you by ExoDx™ Prostate Test for prostate tissue. The ExoDx™ Prostate Test is a simple, non-DRE, urine-based, liquid biopsy test indicated for men 50 years of age and older with a prostate-specific antigen (PSA) 2-10ng/mL, or PSA in the “gray zone” who may be considering a biopsy. The ExoDx Prostate test provides a risk score that determines a patient's potential risk of clinically significant prostate cancer (Gleason Score ≥7). The test is included in the National Comprehensive Cancer Network (NCCN) guidelines and has been clinically validated at the cut-point of 15.6 with a 91% sensitivity and 92% negative predictive value, meaning there is less than a 9% chance of having aggressive prostate cancer below the validated cut-point of 15.6. Ask your urologist about the ExoDx Prostate Test.This episode is also brought to you by AG1 (Athletic Greens). AG1 contain 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, your nervous system, your immune system, your energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines: XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this...

Marc Laniado, Consultant Urologist at with The Focal Therapy Clinic and a leading innovator in imaging led diagnostics and targeted treatments for prostate cancer, joins On Focus in this episode. Marc has been a vocal advocate for the rights of patients to be informed about their treatment choices from his base at Frimley Health, where he is prostate cancer lead at Wexham Park Hospital. He's also a dedicated practitioner in optimising treatment choices for patients, and has built a reputation in identifying and delivering the right treatment for each patient, based on precise diagnostics and comprehensive discussion about lifestyle, aspirations and relationships. He's here today to speak about how some recent media attention on Active Surveillance might be interpreted, and what men diagnosed with localised prostate need to know about their treatment choices.  Marc discusses the ProtecT trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214122

How are you managing your prostate cancer patients on active surveillance? Credit available for this activity expires: 5/25/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/992384?ecd=bdc_podcast_libsyn_mscpedu

On today's episode, the Dr. Geo podcast features Dr. Aditya Bagrodia, a renowned professor in urology and urologic oncology at the Department of Urology at UC San Diego. Dr. Bagrodia's area of expertise includes patients with germ cell tumors and all kinds of urological tumors, such as prostate and bladder cancer. As a podcaster himself, he hosts BackTable Urology, which educates urologic providers on different urologic approaches.During this insightful conversation, Dr. Geo and Dr. Bagrodia delve into the topic of active surveillance in men with prostate cancer. Dr. Bagrodia has his unique protocol to identify the right candidate for active surveillance, and he encourages people with the right pathology to undergo this form of treatment. The discussion covers important aspects, such as determining who is the right candidate for active surveillance and how to approach the decision-making process.Listeners will gain valuable insights into the world of urology and prostate cancer, as well as a unique perspective on active surveillance as an effective form of treatment for prostate cancer patients. Tune in to this episode of the Dr. Geo podcast for an informative and engaging conversation.----------------Thank you to our sponsors.This episode is brought to you by MDxHealth GPS test for prostate tissue. The GPS test is an advanced 17-gene mRNA test to help guide treatment decisions for localized prostate cancer. The test analyzes prostate cancer gene activity to predict disease aggressiveness and provide clinically meaningful endpoints. MDxHealth GPS is a highly personalized assay that quantifies the biologic aggressiveness of the tumor using a 17-gene signature that includes 12 cancer-related genes representative of 4 key biological pathways and 5 reference genes.This episode is also brought to you by AG1 (Athletic Greens). AG1 contain 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, your nervous system, your immune system, your energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how to live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines: XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement...

Martha Dewey Bergren, editor of The Journal of School Nursing, interviews author Anindita Issa and Erin D. Maughan to discuss the article, "Feasibility Assessment of a School Nurse-Led Approach Using Chronic Absenteeism to Establish the School-Based Active Surveillance Process". The article can be found in Volume 39, Issue 2 To view the article, click here.

Interview with Emily Sterbis, MD, and Premal Trivedi, MD, MSc, authors of Inferior Vena Cava Filter Retrieval Rates Associated With Passive and Active Surveillance Strategies Adopted by Implanting Physicians. Hosted by Angel N. Desai, MD, MPH. Related Content: Inferior Vena Cava Filter Retrieval Rates Associated With Passive and Active Surveillance Strategies Adopted by Implanting Physicians

In this episode of BackTable Urology, Dr. Aditya Bagrodia, Dr. Kara Watts (Montefiore Medical Center), Dr. Minhaj Siddiqui (University of Maryland), and Dr. Arvin George (University of Michigan) discuss active surveillance for prostate cancer. --- SHOW NOTES First, the doctors discuss workup for prostate cancer. They usually obtain an MRI prior to the diagnostic biopsy, but this decision may change in the face of inadequate infrastructure, insurance, and resources. Dr. Siddiqui notes that patients may be distressed when first hearing about their diagnosis, as prostate cancer may be the first serious illness they've been diagnosed with. Dr. George recommends discussing the diagnosis in person after pathology is confirmed. Additionally, Dr. Bagrodia uses the WellPrept app to send patients educational material about prostate cancer before they meet with him again. Next, they discuss the general regimen for active surveillance patients within the first year of diagnosis. Dr. Watts orders an MRI 6 months after the diagnostic biopsy because inflammation from biopsy may be present in the first couple of months. Dr. Minhaj believes that deciding on when to do an MRI scan also depends on the patients' preferences and personalities. They also discuss different types of biopsies and the use of confirmatory biopsies. The doctors also agree that removing the term “cancer” from grade group 1 prostate cancer could potentially minimize financial toxicity and patient anxiety. For patients who still want to pursue treatment, Dr. Bagrodia believes that urologists should have the refusal to treat patients who push for inappropriate treatment. Finally, the doctors consider additional factors that may encourage them to consider treatment in low grade prostate cancer, such as a family history of cancer, BRCA mutations, lower urinary tract symptoms, and select molecular biomarkers and pathology characteristics. Dr. George states that the designation of high versus low volume cancer does not matter and should not be a trigger for treatment. Dr. Minhaj notes that for him, younger age is a stronger indication for active surveillance in order to avoid the morbidity of treatment. Finally, the doctors explain their personal active surveillance regimens and tips for transitioning patients with more serious conditions off of active surveillance once their prostate cancers have been proven to be stable. --- RESOURCES WellPrept https://wellprept.com/

As part of the 2022 Prostate Cancer Patient Conference, Dr. Samuel Washington discuss active surveillance of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38562]

As part of the 2022 Prostate Cancer Patient Conference, Dr. Samuel Washington discuss active surveillance of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38562]

As part of the 2022 Prostate Cancer Patient Conference, Dr. Samuel Washington discuss active surveillance of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38562]

As part of the 2022 Prostate Cancer Patient Conference, Dr. Samuel Washington discuss active surveillance of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38562]

As part of the 2022 Prostate Cancer Patient Conference, Dr. Samuel Washington discuss active surveillance of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38562]

As part of the 2022 Prostate Cancer Patient Conference, Dr. Samuel Washington discuss active surveillance of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Education] [Show ID: 38562]

In this podcast, EAU Prostate Cancer Guidelines Panel members Prof. Nicolas Mottet (FR) and Prof. Philip Cornford (GB), have an in-depth discussion on active surveillance in prostate cancer. The two experts elaborate in detail on what active surveillance is, including the difference between active surveillance and watchful waiting, which can often be mis-understood.  Prof. Mottet and Prof. Cornford delve into the importance of maintaining quality of life and the fact that active surveillance does not mean no treatment but is considered if the patient will benefit from it. More information is shared on the guidelines for active surveillance in prostate cancer and how often to repeat biopsies, MRI and PSA testing. Also, vital information about who the good candidates for active surveillance are, such as Gleason 3+3, as well as candidates that it is not suitable for, and the exclusion criteria. Lastly, Prof. Mottet and Prof. Cornford discuss the problem of compliance and look at what data is currently available. 

"Bereuen Sie die Entscheidung zur radikalen Prostatektomie?" Das wurden Langzeitüberlebende eines Prostatakarzinoms Jahre nach Entfernung der Vorsteherdrüse gefragt. Die Ergebnisse verraten einiges darüber, worauf es bei Therapieentscheidungen – neben den "harten" medizinischen Fakten – und bei der Risikokommunikation ankommt. Der Urologe Dr. Valentin Meissner hat die Ergebnisse auf dem Deutschen Krebskongress vorgestellt.

甲状腺⑤ 甲状腺微小乳頭がんとactive surveillance（解　説）日本医科大学 内分泌外科 教授　　杉谷　巌氏　（ききて）東京大学腎臓内分泌内科准教授　　槙田紀子氏

Declan Murphy and Matt Cooperberg debate this controversial issue.

What happens when you treat people with $168,000 a year medicine when most of them will never need treatment, and all of them don't need treatment now

Neil Shore describes his recent controversial paper.

In this episode Dr. Todd Cohen is joined by Geoff McLennan, a board member of Active Surveillance Patients International (ASPI), an advocacy group created by men with prostate cancer for men with prostate cancer. When Geoff was diagnosed with localized prostate cancer he was shocked to hear he could actively watch his cancer and not undergo extensive treatment. Geoff has now been on Active Surveillance for over 10 years. Geoff will discuss his experience living with prostate cancer and ASPI's mission to educate and help ease the burden of fear and anxiety that prostate cancer patients may face. 

PART ONE of THREE Title: Beyond PSA: Utility of a urine gene expression assay for early detection of prostate cancer in the concierge setting Presenter: Dr. Phranq Tamburri, N.M.D. In today's presentation we discuss: • How has the pandemic changed how your practice approaches prostate cancer screening? • With the changing guidelines on PSA screening, how important is PSA in your assessment? • What benefit is there for having 3 genes analyzed in the ExoDx Prostate Test compared a single gene? Learning Objectives: • Review challenges of prostate cancer and importance of early detection • Discuss benefits and limitations of PSA screening • Understand how biomarkers can improve decision-making for early detection of prostate cancer in the concierge setting • Discuss prostate cancer staging and implications for practice About Phranq D Tamburri, NMD Phranq D Tamburri, NMD is the founder of Prostate Second Opinions (PSO). PSO treats an international patient base after one has received often conflicting advice from their urologist (PSA, biopsy, surgery) and their alternative practitioner (no trust in the PSA, “biopsy is dangerous”, treat with natural medicine) regarding prostate cancer. Dr. Tamburri utilizes highly conventional assessment tools such as advanced PSA kinetic calculations, PSA patterns, molecular testing (i.e. The ExoDx Prostate Test) and prostate ultrasound (TRUSP) with color Doppler to advise patients whether a biopsy is reasonable given an elevated PSA or radiation/surgery is best over less invasive treatments. He also specializes in constructing highly personalized Active Surveillance protocols. Dr. Tamburri is a licensed naturopathic physician residing in Arizona. He has been ‘cross-trained' in both conventional and naturopathic principles through his professional career. This includes Phase 4 testing for Merck Pharmaceuticals, tissue transplant procurement surgery, served as Chief Resident at his Alma Mater (Southwest College of Naturopathic Medicine), rotations with Mayo Clinic urologists, and continues to serve as urology professor at SCNM for the past 21 years. Dr. Tamburri is a regular speaker at physician conferences and is highlighted in the annual ‘Men's Health' issue of the prestigious Naturopathic Medicine News & Review (NDNR) regarding the numerous changes in prostate cancer assessment witnessed by the medical system today. Website: https://www.exosomedx.com/ Value of the ExoDx Prostate Test At-Home Collection Kit. Optimize office visits with the ExoDx Prostate Test • In-office OR At-Home collection kits available • Improved workflow • Telemedicine enabled • Easy reporting Learn More: https://www.exosomedx.com/ Disclaimer: This Podcast, it's authors, guests, interviewers, sponsors are not rendering medical, legal or accounting/financial advice. For full disclaimer, please visit: https://conciergemedicinetoday.org/tcpp/

Drs Lidia Schapira and Antonio Wolff discuss the current research on DCIS and other forms of lower-risk early breast cancer, and how medical oncologists can work to create an optimal treatment plan. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963165). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Questions About the BRCA1 and BRCA2 Gene Study and Breast Cancer https://www.genome.gov/10000940/brca1brca2-study-faq Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment https://ascopubs.org/doi/10.1200/JCO.21.01674 Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474966/ Addressing Overtreatment of Screen Detected DCIS; The LORIS Trial https://www.ejcancer.com/article/S0959-8049(15)00697-8/fulltext Feasibility of a Prospective, Randomised, Open-label, International Multicentre, Phase III, Non-inferiority Trial to Assess the Safety of Active Surveillance for Low Risk Ductal Carcinoma In Situ -- The LORD study https://www.ejcancer.com/article/S0959-8049(15)00394-9/fulltext The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) Trial: A Phase III Randomised Controlled Clinical Trial for Low-Risk Ductal Carcinoma In Situ (DCIS) https://bmjopen.bmj.com/content/9/3/e026797.long

Title: Beyond PSA: Utility of a urine gene expression assay for early detection of prostate cancer in the concierge setting Presenter: Dr. Phranq Tamburri, N.M.D. (Webinar) WATCH PART 1: https://youtu.be/_XnqviPeJWM (Webinar) WATCH PART 2: https://youtu.be/onzghpr70Kk (Webinar) WATCH PART 3: https://youtu.be/sKh23GhDwVQ In today's presentation we discuss: • How has the pandemic changed how your practice approaches prostate cancer screening? • With the changing guidelines on PSA screening, how important is PSA in your assessment? • What benefit is there for having 3 genes analyzed in the ExoDx Prostate Test compared a single gene? Learning Objectives: • Review challenges of prostate cancer and importance of early detection • Discuss benefits and limitations of PSA screening • Understand how biomarkers can improve decision-making for early detection of prostate cancer in the concierge setting • Discuss prostate cancer staging and implications for practice About Phranq D Tamburri, NMD Phranq D Tamburri, NMD is the founder of Prostate Second Opinions (PSO). PSO treats an international patient base after one has received often conflicting advice from their urologist (PSA, biopsy, surgery) and their alternative practitioner (no trust in the PSA, “biopsy is dangerous”, treat with natural medicine) regarding prostate cancer. Dr. Tamburri utilizes highly conventional assessment tools such as advanced PSA kinetic calculations, PSA patterns, molecular testing (i.e. The ExoDx Prostate Test) and prostate ultrasound (TRUSP) with color Doppler to advise patients whether a biopsy is reasonable given an elevated PSA or radiation/surgery is best over less invasive treatments. He also specializes in constructing highly personalized Active Surveillance protocols. Dr. Tamburri is a licensed naturopathic physician residing in Arizona. He has been ‘cross-trained' in both conventional and naturopathic principles through his professional career. This includes Phase 4 testing for Merck Pharmaceuticals, tissue transplant procurement surgery, served as Chief Resident at his Alma Mater (Southwest College of Naturopathic Medicine), rotations with Mayo Clinic urologists, and continues to serve as urology professor at SCNM for the past 21 years. Dr. Tamburri is a regular speaker at physician conferences and is highlighted in the annual ‘Men's Health' issue of the prestigious Naturopathic Medicine News & Review (NDNR) regarding the numerous changes in prostate cancer assessment witnessed by the medical system today. Website: https://www.exosomedx.com/ Value of the ExoDx Prostate Test At-Home Collection Kit. Optimize office visits with the ExoDx Prostate Test • In-office OR At-Home collection kits available • Improved workflow • Telemedicine enabled • Easy reporting Learn More: https://www.exosomedx.com/ Disclaimer: This Podcast, it's authors, guests, interviewers, sponsors are not rendering medical, legal or accounting/financial advice. For full disclaimer, please visit: https://conciergemedicinetoday.org/tcpp/

Dr Art Rastinehad joins On Focus to discuss how focal therapy is being implemented in the US, and how US and UK clinicians and researchers are collaborating to advance its development. Dr Art Rastinehad is Director for Prostate Cancer at the Northwell Health Cancer Institute in New York State and the Vice Chair of Urology at Lenox Hill Hospital in New York City. He trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image-guided procedures, prostate artery embolization, laparoscopic and robotic surgery, and he has authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer, including focal therapy. Recent publication - consensus on moving to Focal therapy Active Surveillance: https://pubmed.ncbi.nlm.nih.gov/33676851/ Dr Art Rastinehad's website: https://drrastinehad.com/

Title: Beyond PSA: Utility of a urine gene expression assay for early detection of prostate cancer in the concierge setting Presenter: Dr. Phranq Tamburri, N.M.D. (Webinar) WATCH PART 1: https://youtu.be/_XnqviPeJWM (Webinar) WATCH PART 2: https://youtu.be/onzghpr70Kk (Webinar) WATCH PART 3: https://youtu.be/sKh23GhDwVQ In today's presentation we discuss: • How has the pandemic changed how your practice approaches prostate cancer screening? • With the changing guidelines on PSA screening, how important is PSA in your assessment? • What benefit is there for having 3 genes analyzed in the ExoDx Prostate Test compared a single gene? Learning Objectives: • Review challenges of prostate cancer and importance of early detection • Discuss benefits and limitations of PSA screening • Understand how biomarkers can improve decision-making for early detection of prostate cancer in the concierge setting • Discuss prostate cancer staging and implications for practice About Phranq D Tamburri, NMD Phranq D Tamburri, NMD is the founder of Prostate Second Opinions (PSO). PSO treats an international patient base after one has received often conflicting advice from their urologist (PSA, biopsy, surgery) and their alternative practitioner (no trust in the PSA, “biopsy is dangerous”, treat with natural medicine) regarding prostate cancer. Dr. Tamburri utilizes highly conventional assessment tools such as advanced PSA kinetic calculations, PSA patterns, molecular testing (i.e. The ExoDx Prostate Test) and prostate ultrasound (TRUSP) with color Doppler to advise patients whether a biopsy is reasonable given an elevated PSA or radiation/surgery is best over less invasive treatments. He also specializes in constructing highly personalized Active Surveillance protocols. Dr. Tamburri is a licensed naturopathic physician residing in Arizona. He has been ‘cross-trained' in both conventional and naturopathic principles through his professional career. This includes Phase 4 testing for Merck Pharmaceuticals, tissue transplant procurement surgery, served as Chief Resident at his Alma Mater (Southwest College of Naturopathic Medicine), rotations with Mayo Clinic urologists, and continues to serve as urology professor at SCNM for the past 21 years. Dr. Tamburri is a regular speaker at physician conferences and is highlighted in the annual ‘Men's Health' issue of the prestigious Naturopathic Medicine News & Review (NDNR) regarding the numerous changes in prostate cancer assessment witnessed by the medical system today. Website: https://www.exosomedx.com/ Value of the ExoDx Prostate Test At-Home Collection Kit. Optimize office visits with the ExoDx Prostate Test • In-office OR At-Home collection kits available • Improved workflow • Telemedicine enabled • Easy reporting Learn More: https://www.exosomedx.com/ Disclaimer: This Podcast, it's authors, guests, interviewers, sponsors are not rendering medical, legal or accounting/financial advice. For full disclaimer, please visit: https://conciergemedicinetoday.org/tcpp/

Title: Beyond PSA: Utility of a urine gene expression assay for early detection of prostate cancer in the concierge setting Presenter: Dr. Phranq Tamburri, N.M.D. In today's presentation we discuss: • How has the pandemic changed how your practice approaches prostate cancer screening? • With the changing guidelines on PSA screening, how important is PSA in your assessment? • What benefit is there for having 3 genes analyzed in the ExoDx Prostate Test compared a single gene? Learning Objectives: • Review challenges of prostate cancer and importance of early detection • Discuss benefits and limitations of PSA screening • Understand how biomarkers can improve decision-making for early detection of prostate cancer in the concierge setting • Discuss prostate cancer staging and implications for practice About Phranq D Tamburri, NMD Phranq D Tamburri, NMD is the founder of Prostate Second Opinions (PSO). PSO treats an international patient base after one has received often conflicting advice from their urologist (PSA, biopsy, surgery) and their alternative practitioner (no trust in the PSA, “biopsy is dangerous”, treat with natural medicine) regarding prostate cancer. Dr. Tamburri utilizes highly conventional assessment tools such as advanced PSA kinetic calculations, PSA patterns, molecular testing (i.e. The ExoDx Prostate Test) and prostate ultrasound (TRUSP) with color Doppler to advise patients whether a biopsy is reasonable given an elevated PSA or radiation/surgery is best over less invasive treatments. He also specializes in constructing highly personalized Active Surveillance protocols. Dr. Tamburri is a licensed naturopathic physician residing in Arizona. He has been ‘cross-trained' in both conventional and naturopathic principles through his professional career. This includes Phase 4 testing for Merck Pharmaceuticals, tissue transplant procurement surgery, served as Chief Resident at his Alma Mater (Southwest College of Naturopathic Medicine), rotations with Mayo Clinic urologists, and continues to serve as urology professor at SCNM for the past 21 years. Dr. Tamburri is a regular speaker at physician conferences and is highlighted in the annual ‘Men's Health' issue of the prestigious Naturopathic Medicine News & Review (NDNR) regarding the numerous changes in prostate cancer assessment witnessed by the medical system today. Website: https://www.exosomedx.com/ Value of the ExoDx Prostate Test At-Home Collection Kit. Optimize office visits with the ExoDx Prostate Test • In-office OR At-Home collection kits available • Improved workflow • Telemedicine enabled • Easy reporting Learn More: https://www.exosomedx.com/ Disclaimer: This Podcast, it's authors, guests, interviewers, sponsors are not rendering medical, legal or accounting/financial advice. For full disclaimer, please visit: https://conciergemedicinetoday.org/tcpp/

Title: Beyond PSA: Utility of a urine gene expression assay for early detection of prostate cancer in the concierge setting Presenter: Dr. Phranq Tamburri, N.M.D. (Webinar) WATCH PART 1: https://youtu.be/_XnqviPeJWM (Webinar) WATCH PART 2: https://youtu.be/onzghpr70Kk (Webinar) WATCH PART 3: https://youtu.be/sKh23GhDwVQ In today's presentation we discuss: • How has the pandemic changed how your practice approaches prostate cancer screening? • With the changing guidelines on PSA screening, how important is PSA in your assessment? • What benefit is there for having 3 genes analyzed in the ExoDx Prostate Test compared a single gene? Learning Objectives: • Review challenges of prostate cancer and importance of early detection • Discuss benefits and limitations of PSA screening • Understand how biomarkers can improve decision-making for early detection of prostate cancer in the concierge setting • Discuss prostate cancer staging and implications for practice About Phranq D Tamburri, NMD Phranq D Tamburri, NMD is the founder of Prostate Second Opinions (PSO). PSO treats an international patient base after one has received often conflicting advice from their urologist (PSA, biopsy, surgery) and their alternative practitioner (no trust in the PSA, “biopsy is dangerous”, treat with natural medicine) regarding prostate cancer. Dr. Tamburri utilizes highly conventional assessment tools such as advanced PSA kinetic calculations, PSA patterns, molecular testing (i.e. The ExoDx Prostate Test) and prostate ultrasound (TRUSP) with color Doppler to advise patients whether a biopsy is reasonable given an elevated PSA or radiation/surgery is best over less invasive treatments. He also specializes in constructing highly personalized Active Surveillance protocols. Dr. Tamburri is a licensed naturopathic physician residing in Arizona. He has been ‘cross-trained' in both conventional and naturopathic principles through his professional career. This includes Phase 4 testing for Merck Pharmaceuticals, tissue transplant procurement surgery, served as Chief Resident at his Alma Mater (Southwest College of Naturopathic Medicine), rotations with Mayo Clinic urologists, and continues to serve as urology professor at SCNM for the past 21 years. Dr. Tamburri is a regular speaker at physician conferences and is highlighted in the annual ‘Men's Health' issue of the prestigious Naturopathic Medicine News & Review (NDNR) regarding the numerous changes in prostate cancer assessment witnessed by the medical system today. Website: https://www.exosomedx.com/ Value of the ExoDx Prostate Test At-Home Collection Kit. Optimize office visits with the ExoDx Prostate Test • In-office OR At-Home collection kits available • Improved workflow • Telemedicine enabled • Easy reporting Learn More: https://www.exosomedx.com/ Disclaimer: This Podcast, it's authors, guests, interviewers, sponsors are not rendering medical, legal or accounting/financial advice. For full disclaimer, please visit: https://conciergemedicinetoday.org/tcpp/

Dr. Refky Nicola interviews Dr. Nicola Schieda. Active Surveillance of Renal Masses: The Role of Radiology. Schieda and Krishna et al. Radiology 2022; 302:11–24. 

“Dr. Christopher Warlick is an associate professor and chairman of the urology University of Minnesota Department serving as the first Black chairman at the institution. He received his MD/PHD from the  University of Minnesota (M.D., Ph.D.) and completed his urology residency at Johns Hopkins Medical Institutions, Baltimore MD (Urology). He is a nationally recognized leader in Active Surveillance for low-risk prostate cancer as well as the use of MR imaging in prostate cancer, the development of novel tests to help determine early signs of disease progression, and on programs to increase the use of shared decision making around PSA screening and prostate cancer treatment decision making.”

This one really slipped under the radar when the National Comprehensive Cancer Centre Network (NCCN) Prostate Cancer Guideline Panel released their updated guidelines a few weeks ago. That is until Dr Dan Lin mentioned it to Dr Matt Cooperberg, who promptly flagged it to his very large Twitter following. And what a reaction! Almost universally panned by the urological community, especially advocates for active surveillance (AS), who have long despaired at the low rates of AS uptake in the US, and who worry that this change may lead to even lower rates of AS in the USA. We are joined again today by Dr Matt Cooperberg (Urologist, UCSF), and Dr Ashley Ross (Urologist, Northwestern Medical Group, Chicago), to have an in-depth discussion on this. Usual hosts Declan Murphy and Renu Eapen do their best to stay impartial! Our prediction is that NCCN will change this back at the next opportunity....Also posted on YouTube for those who like to watch facial reactions! Links:Matt Cooperberg's TweetNCCN Guideline on prostate cancer (login needed)MedPage Today report

September is Prostate Cancer Awareness Month ***Ingrid J. Hall, PhD, MPH, is an epidemiologist in the Division of Cancer Prevention and Control's Epidemiology and Applied Research Branch. Dr. Hall's current research focus is in the area of minority health, particularly finding culturally relevant ways to publicize the need for participation in cancer screening and early detection by minority populations. Dr. Hall has a long history of published work in the area of prostate cancer decision making and spearheaded the organization and coordination of the State of the Science Conference on Active Surveillance in the Management of Localized Prostate Cancer convened in 2010. She currently oversees studies developing an interactive online educational tool for prostate cancer treatment choices as well as support materials for newly diagnosed men who choose active surveillance. ***Otis Brawley is professor of oncology at the Johns Hopkins University School of Medicine and 39th Bloomberg Distinguished Professor at Johns Hopkins. Dr. Brawley leads a broad interdisciplinary research effort of cancer health disparities at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, working to close racial, economic and social disparities in the prevention, detection and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland as the Kimmel Cancer Center's associate director for community outreach and engagement.  

Prostate cancer is currently getting diagnosed at a rate of one in nine men. Not all prostate cancers are alike, however. Some are more aggressive and require intervention, while others could be slow-growing with low risk. If you have been diagnosed with early-stage, low-risk prostate cancer, your urologist might talk to you about active surveillance as a viable option for your situation.  Active surveillance got introduced by several pioneers in the field, including Dr. Laurence Klotz. Dr. Klotz has long been considered the father of active surveillance. Dr. Pohlman was able to chat with Dr. Klotz at the 30th Annual International Prostate Cancer Update in Beaver Creek, Colorado.  Today, we are bringing that interview from episode 8 out of the vault. In it, Dr. Klotz talks about everything you need to know about active surveillance, including the men who may be candidates for that option and what is involved with the protocol. Be sure to stay tuned today to find out what Dr. Klotz has to say about active surveillance for low-risk prostate cancer. About Dr. Klotz: Dr. Klotz currently serves as Professor of Surgery at the University of Toronto. He also holds the Sunnybrook Chair of Prostate Cancer Research, and he is the chairman of the World Uro-Oncology  Federation. Dr. Klotz was the Founding Editor-in-Chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal. He was the founder and is Chairman of the Canadian Urology Research Consortium. He was awarded the Order of Canada for his work in prostate cancer. Dr. Klotz completed his fellowship at the Memorial Sloan Kettering Cancer Center in New York in urologic oncology. Dr. Klotz is a widely published urologic oncologist with over 350 publications and six books. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show highlights: Dr. Klotz explains what active surveillance is. In most men over the age of sixty-five with small amounts of low-grade prostate cancer, it never spreads. Dr. Klotz discusses the issue with low-grade prostate cancer. Dr. Klotz shares the basis for the concept of active surveillance. Dr. Klotz shares some of the advantages of doing active surveillance rather than having treatment. Dr. Klotz explains how doctors identify the men who would be candidates for active surveillance. What men can expect from going on an active surveillance protocol. Dr. Klotz explains what the term “watchful waiting” means. Active surveillance first got started approximately twenty-two years ago. Dr. Klotz explains what the options for men with low-grade prostate cancer were before that. Dr. Klotz explains why time is such a powerful tool when treating serious diseases. The concept of active surveillance has also been influential in other fields, like thyroid, breast, and kidney cancers. Links and resources: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link here, on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up for the wait-list for our bonus video content.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.

In this episode, Dr. Laurence Klotz, Professor of Surgery at the University of Toronto, sits down with Dr. Todd Cohen to discuss his role in the advancement of Active Surveille in Urology. He dives into how himself and two colleagues came up with a strategy to reduce over treatment in prostate cancer patients. Dr. Klotz will also talk about the early controversy surrounding Active Surveillance and how he has dealt with patient anxiety. 

Today, we have the renowned prostate cancer expert, Dr. Laurence Klotz joining us on the Prostate Health Podcast. It can be very distressing to receive a diagnosis of prostate cancer. For many men, their first instinct is to immediately want to go for aggressive therapy, like surgery or radiation. Active surveillance, however, has become a valuable alternative for some men with low-risk prostate cancer because it allows them to avoid some of the side-effects of cancer treatment. Listen in today, to find out all you need to know about active surveillance for prostate cancer. Dr. Klotz currently serves as Professor of Surgery at the University of Toronto. He also holds the Sunnybrook Chair of Prostate Cancer Research and he is the chairman of the World Uro-Oncology  Federation.  Dr. Klotz was the Founding Editor-in-Chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal. He was the founder and is Chairman of the Canadian Urology Research Consortium. He was awarded the Order of Canada for his work in prostate cancer. Dr. Klotz completed his fellowship at the Memorial Sloan Kettering Cancer Center in New York, in urologic oncology.  Dr. Klotz is a widely published Urologic Oncologist with over 350 publications and six books. Be sure to tune in today, to find out what he has to share about active surveillance for low-risk prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.  Show Highlights: Dr. Klotz shares some key points which are the basis for this conservative approach to the treatment of prostate cancer. Low-grade prostate cancer normally develops with age, in men. A man's likelihood of having low-grade cancer in his prostate is roughly equal to his age, as a percentage. Although about two-thirds of men over the age of sixty-five will have small amounts of low-grade prostate cancer, studies have shown that this low-grade prostate cancer has a zero chance of metastasizing. It never spreads. Dr. Klotz explains what the issue is with low-grade prostate cancer. Dr. Klotz discusses the major approach to active surveillance. Some of the advantages of doing active surveillance, rather than having treatment. Dr. Klotz explains how doctors identify men who are candidates for active surveillance. The basic protocols around active surveillance, and how they are applied, vary to some degree around the world. The whole approach to low-grade prostate cancer has improved a lot. The current trend is moving away from doing biopsies. For patients of around eighty years of age, doctors switch to what's known as “watchful waiting”. Dr. Klotz explains what that means. Active surveillance is now also being used for several other types of cancers. Links and resources: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd To get your free What To Expect Guide, go to www.prostatehealthpodcast.com/clinic  Or find the link on our podcast website - www.prostatehealthpodcast.com